51
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

, , &
Pages 959-965 | Published online: 28 May 2015

References

  • BresslerNMBresslerSBCongdonNGPotential public health impact of Age-Related Eye Disease Study results: AREDS report no 11Arch Ophthalmol20031211621162414609922
  • rcophth.ac.uk [homepage on the Internet]LondonThe Royal College of Ophthalmologists2009 [cited 2013]. Available from: http://www.rcophth.ac.ukAccessed April 17, 2014
  • BrownDMRegilloCDAnti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patientsAm J Ophthalmol2007144462763717893015
  • RosenfeldPJBrownDMHeierJRanibizumab for Neovascular Age-Related Macular DegenerationN Engl J Med20063551419143117021318
  • BrownDMMichelsMKaiserPKRanibizumab versus verteporfin photodynamic therapy for neovascular ade-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology20091161576519118696
  • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
  • LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related maculuar degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
  • MałgorzataFStankiewiczAEffectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomesMed Sci Monit2011179CR48549021873944
  • ShienbaumGGarcia FilhoCAFlynnHWJrNunesRPSmiddyWERosenfeldPJManagement of submacular hemorrage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapyAm J Ophthalmol201315561009101323465269
  • CohenSYDuboisLTadayoniRResults of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical settingAm J Ophthalmol2009148340941319477713
  • DadgostarHVenturaAAChungJYSharmaSKaiserPKEvaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degenerationOphthalmology200911691740174719643484
  • QuerquesGAzryaSMartinelliDRanibizumab for exudative age-related macular degeneration: 24 month outcomes from a single centre institutional settingBr J Ophthalmol201094329229619951942
  • BandukwalaTMuniRHSchwartzCEngKTKertesPJEffectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective reviewCan J Ophthalmol201045659059521135894
  • KangSRohYJOne-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroupsJpn J Ophthalmol200953438939519763757
  • SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)2010241708171520885427
  • HjelmqvistLLindbergCKanulfPDahlgrenHJohanssonISiewertAOne-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrispective observational multicentre studyJ Ophthalmol2011201140572422174994
  • FengXFConstableIJMcAllisterILIsaacsTComparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degenerationInt J Ophthalmol201141858822553617